Back to top
more

AEterna Zentaris (AEZS)

(Delayed Data from NSDQ)

$1.95 USD

1.95
4,327

0.00 (-0.19%)

Updated Apr 29, 2024 01:58 PM ET

After-Market: $1.95 0.00 (-0.13%) 5:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Aeterna Zentaris (AEZS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of -450.00% and -99.12%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for AEterna (AEZS) This Earnings Season?

by Zacks Equity Research

AEterna (AEZS) may provide update on the path forward for Macrilen in Europe on the first-quarter earnings call.

Analysts Estimate Aeterna Zentaris (AEZS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Aeterna Zentaris (AEZS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aeterna Zentaris (AEZS) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Aeterna Zentaris (AEZS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What's in the Cards for Aeterna (AEZS) This Earnings Season?

by Zacks Equity Research

Aeterna (AEZS) growth hormone deficiency test, Macrilen, to drive revenues in the fourth quarter.

The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris

Nitish Marwah headshot

4 Drug Stocks to Buy Despite Price Hearing Woes

by Nitish Marwah

A burgeoning economy has necessitated diversification by the top players in the industry. Given such positives, any decision to lower drug prices will not hamper the space.

The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

by Zacks Equity Research

The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

Swarup Gupta headshot

5 Tiny Biotech Stocks With Superb Growth Potential

by Swarup Gupta

A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.

Is AEterna Zentaris (AEZS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (AEZS) Outperforming Other Medical Stocks This Year?

Implied Volatility Surging for Aeterna Zentaris (AEZS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Aeterna Zentaris (AEZS) stock based on the movements in the options market lately.

Amgen's Osteoporosis Candidate Evenity Gets Approval in Japan

by Zacks Equity Research

Amgen (AMGN) gets approval in Japan for osteoporosis candidate, Evenity.

Is AEterna Zentaris (AEZS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (AEZS) Outperforming Other Medical Stocks This Year?

AEterna Zentaris Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

AEterna Zentaris has been struggling lately, but the selling pressure may be coming to an end soon.

Aeterna Zentaris (AEZS) Stock Moves -1.16%: What You Should Know

by Zacks Equity Research

In the latest trading session, Aeterna Zentaris (AEZS) closed at $2.56, marking a -1.16% move from the previous day.

Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AEZS) Outperforming Other Medical Stocks This Year?

Aeterna Zentaris (AEZS) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Aeterna Zentaris (AEZS) closed at $2.90, marking a +1.75% move from the previous day.

Aeterna Zentaris (AEZS) Stock Moves -0.54%: What You Should Know

by Zacks Equity Research

Aeterna Zentaris (AEZS) closed at $3.67 in the latest trading session, marking a -0.54% move from the prior day.

Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AEZS) Outperforming Other Medical Stocks This Year?

Can The Uptrend Continue for Aeterna Zentaris (AEZS)?

by Zacks Equity Research

Investors certainly have to be happy with Aeterna Zentaris Inc. (AEZS) and its short term performance.

Mirati Therapeutics (MRTX) Soars: Stock Adds 13.6% in Session

by Zacks Equity Research

Mirati Therapeutics (MRTX) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes.

    VIVUS (VVUS) in Focus: Stock Moves 5.6% Higher

    by Zacks Equity Research

    VIVUS (VVUS) was a big mover last session, as the company saw its shares rise nearly 6% on the day.

      MiMedx Group (MDXG) Soars: Stock Adds 11.2% in Session

      by Zacks Equity Research

      MiMedx Group (MDXG) shares rose more than 11% in the last trading session, amid huge volumes.

        Inovio Pharmaceuticals (INO) in Focus: Stock Moves 5.7% Higher

        by Zacks Equity Research

        Inovio Pharmaceuticals (INO) was a big mover last session, as the company saw its shares rise nearly 6% on the day.

          Zacks.com highlights: Weight Watchers International, Aeterna Zentaris, TransUnion, Six Flags Entertainment and Johnson Outdoors

          by Zacks Equity Research

          Zacks.com highlights: Weight Watchers International, Aeterna Zentaris, TransUnion, Six Flags Entertainment and Johnson Outdoors